9-Mar-2026
Pfizer reports positive data from a Phase 2 study for the atopic dermatitis antibody
Seeking Alpha News (Mon, 9-Mar 10:44 AM ET)
Top 10 healthcare stocks with highest dividend yield amid volatile markets
Seeking Alpha News (Mon, 9-Mar 10:19 AM ET)
Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis
Business Wire (Mon, 9-Mar 6:45 AM ET)
FDA plans to relax testing rules to encourage biosimilar drugs: report
Seeking Alpha News (Mon, 9-Mar 6:44 AM ET)
Roche stock falls after breast cancer combo therapy fails in trial
Seeking Alpha News (Mon, 9-Mar 6:21 AM ET)
Pfizer Stock Watch: New Drug Trials Aim to Reignite Growth
TipRanks (Sat, 7-Mar 10:02 AM ET)
FDA vaccine chief to leave the agency again
Seeking Alpha News (Sat, 7-Mar 7:41 AM ET)
Pfizer Adds New Early-Stage Heart Failure Candidate to Its China Pipeline
TipRanks (Fri, 6-Mar 11:32 AM ET)
Pharma giants pressed by Senate Democrats over Trump pricing deals
Seeking Alpha News (Fri, 6-Mar 10:45 AM ET)
Markets AM Need to Know: AI chip permits, Iran leadership, oil prices, and more
Seeking Alpha News (Fri, 6-Mar 6:25 AM ET)
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Pfizer trades on the NYSE stock market under the symbol PFE.
As of March 9, 2026, PFE stock price declined to $26.81 with 39,745,108 million shares trading.
PFE has a beta of 0.67, meaning it tends to be less sensitive to market movements. PFE has a correlation of 0.16 to the broad based SPY ETF.
PFE has a market cap of $152.42 billion. This is considered a Large Cap stock.
Last quarter Pfizer reported $18 billion in Revenue and $.66 earnings per share. This beat revenue expectation by $688 million and exceeded earnings estimates by $.10.
In the last 3 years, PFE traded as high as $42.22 and as low as $20.92.
The top ETF exchange traded funds that PFE belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
PFE has underperformed the market in the last year with a return of +8.7%, while SPY returned +19.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PFE shares. However, PFE has outperformed the market in the last 3 month and 2 week periods, returning +4.6% and +0.6%, while SPY returned -0.8% and -1.6%, respectively. This indicates PFE has been having a stronger performance recently.
PFE support price is $26.65 and resistance is $27.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PFE shares will trade within this expected range on the day.